Moderna, a Cambridge, Massachusetts-based biotechnology company, announces that it has been awarded funding to develop a messenger RNA (mRNA)-based coronavirus vaccine. The vaccine was designed in collaboration with The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), will be developed in partnership with the Coalition for Epidemic Preparedness Innovations  (CEPI).  As part of the partnership, NIAID will conduct a Phase I clinical study in the U.S. Source